Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

BACKGROUND: Mutations affecting RAS genes are now established predictive markers of nonresponse to anti-EGFR antibodies in advanced CRC. This analysis assessed the prognostic and predictive impact of extended RAS and PIK3CA gene mutation status in patients receiving capecitabine plus or minus bevaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, T J, Bruhn, M A, Lee, C K, Hardingham, J E, Townsend, A R, Mann, K P, Simes, J, Weickhardt, A, Wrin, J W, Wilson, K, Gebski, V, Van Hazel, G, Robinson, B, Cunningham, D, Tebbutt, N C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366893/
https://www.ncbi.nlm.nih.gov/pubmed/25742472
http://dx.doi.org/10.1038/bjc.2015.37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366893/
https://www.ncbi.nlm.nih.gov/pubmed/25742472
http://dx.doi.org/10.1038/bjc.2015.37

Ejemplares similares